Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 5, 2004 - Issue 8
Submit an article Journal homepage
168
Views
17
CrossRef citations to date
0
Altmetric
Drug Evaluation

Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia

Petro E Petrides Hematology Oncology Center, Zweibruckenstr. 2, 80331 Munich, Germany. [email protected]
Pages 1781-1798 | Published online: 25 Feb 2005

Bibliography

  • SCHAFER A: Thrombocytosis. N Engl. Med. (2004) 350:1211–1219.
  • ••An up-to-date review onthrombocythaemia.
  • Molecular basis of chronic myeloproliferative disorders. Petrides PE, Pahl HL (Eds), Springer Publ. Co., Heidelberg, New York (2004) (In Press).
  • ••A meeting report for those interested inmolecular aspects of the cMPDs.
  • AOP Vienna, Data on File.
  • FLEMING JS, BUYNISKI JP: A new potent inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL-4162A). Thromb. Res. (1979) 15:373–388.
  • •The first detailed report of the anti-aggregating properties of anagrelide in animal and human platelet-rich plasma.
  • TANG SS, FROJMOVIC MM: Inhibition of platelet function by antithrombotic agents which selectively inhibit low km cyclic 3, 5'-adenosine monophosphate phosphodiesterase. I Lab. Clin. Med. (1980) 95:241–257.
  • CLARK WF, REID BD, TEVAARWERK GJ: Anagrelide: inhibitor of collagen and immune complex induced platelet aggregation and release. Thromb. Res. (1981) 21:215–219.
  • CLARK WE TEVAARWERK GJ, MORIARITY TA, REID BD: Inhibitors of immune complex induced human platelet aggregation and release in plasma. Thromb. Res. (1982) 28:681–688.
  • SMITH JB: Effect of thromboxane synthetase inhibitors on platelet function: enhancement by inhibition of phosphodiesterase. Thromb. Res. (1982) 28:477–485.
  • SEILER S, ARNOLD AJ, GROVE RI et al.: Effects of anagrelide on platelet cAMP levels, cAMP dependent protein kinase and thrombin induced Calcium fluxes. Pharmacol Exp. Ther. (1987) 243:767–774.
  • •Report on the mechanism of action of anagrelide in platelets.
  • GILLESPIE E: Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity. Biochem. Pharmacol (1988) 37:2866–2868.
  • GROVE RI, EULER CC, STANTON HC: Anagrelide, a potent inhibitor of platelet aggregation inhibits inositol phosphate generation and elevates cAMP. 76h Annual Meeting of the Federation of American Societies for Experimental Biology (1986) Abstract 394.
  • COURTWRIGHT WE, BUCHANON JO, FLEMING JS, TAYLOR R: The effect of multiple oral doses of anagrelide on ADP and collagen-induced platelet aggregation in normal male subjects. Clin. Pharmacol Thec (1983):220 (Abstract).
  • •Doses of anagrelide 6–8 mg/day inhibit ADP- and collagen-induced aggregation in humans (no full paper available).
  • COLTON DG, PAIGE JB, FLEMING JS, BUYNISKI JP: Effect of the antithrombotic agent anagrelide (AL) on thrombin-stimulated human platelet arachidonic acid (AA) metabolism. Fed. Amer. Soc. Exp. Biol. (1982) Abstract 7557.
  • BALDUINI CL, BERTOLINO G, NORIS P, ASCARI E: Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica (1992) 77:40–43.
  • •The first European report on the treatment with anagrelide.
  • HARRISON P: Progress in the assessment of platelet function. ELI Haematol (2000) 111:733–744.
  • DRESCHER CW, CHUCALES AG, GROCOCK AM, LUCCHESI BR: The effects of BL-4162A on the development of coronary artery thrombosis in the conscious rat. Clin. Res. (1979) 27:716A.
  • BERGER A, ARNOLD J, DUKSTEIN W et al.: 111Indium labelled autologous platelet survival during aggregation inhibition by anagrelide in normal volunteers. Clin. Pharm. The]: (1983) 33: 219.
  • PLAPP F, SINOR L, SCHMITZ R et al: Effect of anagrelide on platelet counts and size. Clin. Pharmacol The]: (1983) 33:223 (Abstract C52).
  • TAYLOR R, FLEMING S, ARNOLD J: The effect on platelets of a stable orally active imidazoquinazoline. Clin. Pharmacol (1984) 24:423 (Abstract).
  • •Studies on nearly 100 male volunteers given anagrelide 6 mg/day.
  • ANDES WA, NOVECK RJ, FLEMING JS: Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb. Hemostasis (1984) 52:325-328. Low anagrelide dosages cause a mild decrease in the platelet count in humans.
  • HERRON KJ, FLEMING JS, SOLBERG LA: Inhibition of megakaryocyte colonies in vitro by anagrelide. Clin. Res. (1986) 34:459.
  • SOLBERG LA, TEFFERI A, OLES KJ et al.: The effects of anagrelide on human megakaryocytopoiesis. Br. Haematol (1997) 99:174–180.
  • •Clinical study on bone marrow aspirates showing that anagrelide interferes with the maturation of megakaryocytes.
  • MAZUR EM, ROSMARIN AG, SOHL PA et al.: Analysis of the mechanism of anagrelide induced thrombocytopenia in humans. Blood (1992) 79:1931–1937.
  • •Experimental studies on megakaryocyte cultures.
  • BELLUCCI S, LEGRAND C, BOVAL B, DROUET L, CAEN J: Studies on platelet volume, chemistry and function in patients with essentiell thrombocythemia treated with anagrelide. Br. Haematol (1999) 104:886–892.
  • ••Biochemical studies on platelets of patientswhilst on anagrelide therapy.
  • LEV PR, MARTA RE VASSALLU P, MOLINAS FC: Variation of PDGF, TGF-6 and bFGF levels in essential thrombocythemia patients treated with anagrelide. Am. Hematol (2002) 70:85–91.
  • LAGUNA MS, KORNBLIHTT LI, MARTA RE MOLINAS FC: Thromboxane B2 and platelet derived growth factor in essential thrombocythemia treated with anagrelide. Medicina (B Aires) (2000) 60:448–452.
  • TOMER A, STAHL RL, HARKER LA: Anagrelide normalizes platelet count in essential thrombocythemia by decreasing megakaryocyte hypermaturation. Blood (1991) 78\(Suppl. 1):145a (Abstract 570).
  • TOMER A: Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood (2002) 99:1602–1609.
  • ••Ex vivo studies on megakaryocytes ofpatients on anagrelide treatment.
  • THIELE J, KVASNICKA HM, SCHMITT-GRAFF A: Anagrelide induzierte Veränderungen der Megakaryopoiese bei der Therapie thrombozythämischer chronischer myeloproliferativer Erkrankungen. Pathologe (2002) 23:426–432.
  • THIELE J, KVASNICKA HM, FUCHS N, BRUNNBAUER K, VOLKWEIN N, SCHMITT- GRAEFF A: Anagrelide induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. An immunohistochemical and morphometric study of sequential trephine biopsies. Haematologica (2003) 88:1130–1138.
  • ••Bone marrow histology of patients treatedwith anagrelide.
  • YOON S-Y, LI C-Y, MESA RA, TEFFERI A: Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br. Haematol (1999) 106:682–688.
  • KASTNER PR, FLEMING JS, GILLESPIE E et al: Inotropic and cardiovascular effects of anagrelide. Proc. Fed. Amer. Soc. Exp. Biol. (1985) 44:716.
  • SILVERSTEIN MN, PETITT RM, SOLBERG LA, FLEMING JS, KNIGHT RC, SCHACTER LP: Anagrelide: new drug for treating thrombocytosis. N Engl. Med. (1988) 318:1292–1294.
  • ••First report on the efficiency of anagrelidein patients with PT.
  • GAVER RC, DEEB G, PITTMAN KA, SMYTH RD: Disposition of anagrelide, an inhibitor of platelet aggregation. Clin. Pharm. Ther. (1981) 29:381–386.
  • •The only published study dealing with the metabolism of anagrelide.
  • PETRIDES PE, TRAPP O, BEYKIRCH MK: Anagrelide (Agrelin): Pharmakologisches Profil und Klinische Anwendung. Der Onkologe (1997) 3:298–302.
  • LANE WJ, HATTORI K, DIAS S et al: Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation. Exp. Hematol (2001) 29:1417–1424.
  • ••An important although debated studyaddressing the role of metabolites for the action of anagrelide in man.
  • ERUSALIMSKI JD, HONG Y, FRANKLIN R: Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5,6-dichloro-3,4-dihydroquinazoline (RL603)? Exp. Hematol (2002) 30:625–626.
  • ••Refusal of the role of FL603.
  • ERUSALIMSKI JD, WANG G, HONG Y: The anagrelide metabolite 2-amino-5,6-dichloro-3,4-dihydroquinazoline (RL603) is a poor inhibitor of in vitro megakaryopoiesis. American Society of Hematology. Blood (2002) (Abstract 4950).
  • MCCARTY JM, MELONE PM, HEISEY C, DESSYPRIS EN: Differences in the species specific activity of anagrelide is mediated through the c-mpl receptor. Blood (2000) 96:743a.
  • •An important hypothesis of the mechanism of action of anagrelide (unfortunately no full paper available).
  • RAFIL S, LANE W: In Response. Exp. Hematol (2002) 30:626–627.
  • KERNS EH: Determination of anagrelide in plasma by capillary gas chromatography - mass spectrometry. Chromatography (1987) 416:357–364.
  • PETRIDES PE, BEYKIRCH MK: Efficacy of platelet reduction by anagrelide and safety of this drug in patients with primary thrombocythemia and other CMPDs: an overview of nine prospective non-randomized trials. Hematol (2001) 2:16.
  • ANAGRELIDE STUDY GOUP: Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am. J. Med. (1992) 92:69–76.
  • ••A large series of patients with cMPDstreated with anagrelide.
  • PETITT RIVI, SILVERSTEIN MN, PETRONE M: Anagrelide for control of thrombocythemia in polycythemia vera and other myeloprolferative disorders. Sem. Hematol (1997) 34:51–54.
  • MAZZUCONI MG, DESANCTIS V, CHISTOLINI A et al.: Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. Hematologica (1992)77:315–317.
  • PETRIDES PE, BEYKIRCH MK, TRAPP OM: Anagrelide, a novel platelet lowering option in essential thrombocythemia: treatment experience in 48 patients in Germany. Ear: Hematol (1998) 61:71–76.
  • ••The first large European study on patientswith essential thrombocythaemia.
  • PETRIDES PE, BEYKIRCH MK: Long term follow up of patients with essential thrombocythemia under treatment with anagrelide. American Society of Hematology. Blood (1999) 94: (Supp1.1): (Abstract 4519).
  • SIEGEL F, PETRIDES PE: Long term analysis of patients with primary thrombocythemia treated with anagrelide for up to 14 years. (In Preparation).
  • TRAPP OM: Anagrelide: emn neuer Wirkstoff zur Behandlung primärer Thrombozythämien. Ludwig-Maximilians-Universität Munchen (1999) (Doctoral Thesis).
  • TRAPP OM, BEYKIRCH MK, PETRIDES PE: Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count. Blood Cells MM. Dis. (1998) 24:9–13.
  • •Study showing the efficient normalisation of the platelet count in CML patients refractory to hydroxyurea.
  • BURKHARD H, ADAM H, WIDMER L et al.: Anagrelide zur Kontrolle der Myeloproliferativen Thrombozythämie: Langzeiterfahrung bei 6 Patienten. Schweiz. Med. Wochenschr. (1998) 128:1808–1812.
  • MILLS AK, TAYLOR KM, WRIGHT SJet al.: Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythemia. Aust. N41. Med. (1999) 29:29–37.
  • LAGUNA MS, KORNBLIHTT LI, MARTA RF et al.: Effectiveness of Anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Appl Thrombosis/Hemostasis (2000) 6:157–161.
  • KNUTSEN H, HYSING J: Anagrelide ved primaer trombocytemi. Tidsskr Nor Lageforen (2001) 212:1478–1482.
  • GISSLINGER H: Use of Anagrelide as monotherapy or in combination with interferon-a or hydroxyurea. Results of the study AOP 02007. German-Austrian Annual Hematology Oncology Meeting, AOP-Symposium, Munich (2002).
  • STEURER M, GASTL G, JEDRCZEJCZAK W et at Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile (Submitted).
  • GREEN A, PEARSON T: Position paper on anagrelide. British Society of Hematology, February (2000).
  • SILVERSTEIN MN: Anagrelide in myeloproliferative diseases. In: Polycythemia vera and the myeloproliferative disorders. Wasserman LR, Berk PD, Berlin NI (Eds), Saunders, Philadelphia, USA (1995):329–336.
  • LENGFELDER E, HOCHHAUS A, KRONAWITTER U et al: Should a platelet limit of 600 x 109/L be used as a diagnostic criterion in essential thrombocythemia? An analysis of the natural course including early stages. Br: J. Haematol (1998) 100:15–23.
  • •Deals with the early often neglected stages of PT.
  • SACCHI S, VINCI G, GUGLOTTA L et al.: Diagnosis of essential thrombocythemia at platelets counts between 400 and 600 x 109/L. Haematologica (2000) 85:492–495.
  • REGEV A, STARK P, BLICKSTEIN D et al.: Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am. Hematol . (1997) 56:168–172.
  • ••Complications can occur at low plateletcounts.
  • PETRIDES PE: Pathogenesis of the complications of cMPDs: identification of risk factors. German-Austrian Annual Hematology Oncology Meeting, AOP-Symposium, Munich, Germany (2002).
  • NIMER SD: Essential thrombocythemia: another 'heterogeneous disease' better understood? Blood (1999) 93:415–416.
  • RUIZ-ARGUELLES GJ, RUIZ-DELGADO GJ, RUIZ-REYES G, CHERNOFF SG: Anagrelide induced relapse of a hydroxyurea induced leg ulcer in a patient with primary thrombocythemia. Mayo Clinic Proc. (1998) 73:1125.
  • WIRTH K, SCHOEPF E, MERTELSMANN R et al.: Leg ulceration with associated thrombocytosis: healing of ulceration associated with treatment of the raised platelet count. Br. J. Haematol (1998) 138:533–535.
  • JAMES CW: Anagrelide induced cardiomyopathy. Pharmacotherapy (2000) 20:1224–1227.
  • BRAESTER A, LAVER B: Anagrelide-induced erectile dysfunction. Ann. Pharmacother. (2002) 36:1291.
  • RHAGA WAN M, MAZER MA, BRINK DJ: Severe hypersensivity pneumonitis associated with anagrelide. Ann. Pharmacother. (2003) 37:1228–1231.
  • SWORDS R, FAY M, O'DONNELL R, MURPHY PT: Anagrelide induced visual hallucinations in a patient with essential thrombocythemia. Eur: .1. Haematol (2004) (In Press).
  • PETRONE ME, WILSON J, PETITT RM, SILVERSTEIN MN: Anagrelide for treatment of thrombocythemia. Br. J. Haematol (1996) 93 (Suppl. 2):237.
  • SILVERSTEIN MN, PETRONE ME, PETITT RM, DEMENT MP, VUKOVICH RA: The safety profile of anagrelide for treatment of thrombocythemia. Blood (1996) 88\(Suppl. 1):583a.
  • SILVERSTEIN MN, TEFFERI A: Treatment of essential thrombocythemia with anagrelide. Sem. Hematol (1999) 36\(Suppl. 2):23–25.
  • STOREN EC, TEFFERI A: Long term use of anagrelide in young patients with essential thrombocythemia. Blood (2001) 97:863–866.
  • ••Important analysis of long-term use inyoung patients.
  • KORNBLIHTT LI, VASSALLU PS, HELLER P, MOLINAS FC: Treatment of essential thrombocythemia with anagrelide: a ten year experience. Medicine ( Aires) (2002) 62:231–236.
  • BIRGEGARD G, BJORKHOLM M, KUTTI J et al.: Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica (2004) 89:520–527.
  • ROSENBAUM H, BENNETT M, BRAESTER A et al: Toxicity of treatment with anagrelide for thrombocytosis in myeloproliferative disorders. American Society of Hematology. Blood (2002) (Abstract 3151).
  • FRUCHTMAN SM, PETITT RM, GILBERT HS, FIDDLER G, LYNE A: Anagrelide. Analysis of long term safety and leukemogenic potential in myeloproliferative diseases (MPDs). American Society of Hematology. Blood (2002) (Abstract 256).
  • MCCUNE JS, LILES D, LUINDLEY C: Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations. Pharmacotherapy (1997) 17:822–826.
  • MCCUNE JS, LILES D, LUINDLEY C: Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations-Author's reply. Pharmacotherapy (1998) 18:660–661.
  • PETITT R: Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations - a comment. Pharmacotherapy (1998) 18:659.
  • CORTELAZZO S, MARCHETTI M, ORLANDO E et al.: Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipoxygenase pathway. Am. J. Hematol (1998) 57:277–282.
  • •Deals with the different response of patients with PT to aspirin.
  • TSIMBERIDOU AM, COLBURN DE, WELCH MA et al. : Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother. Pharmacol (2003) 52:229–234.
  • VOSKARIDOU E, TERPOS E, KOMNINAKA V, EFTYHIADIS E, MANTZOURANI M, LOUKOPOULOS D: Chronic myeloid leukemia with marked thrombocytosis in a patient with thalassemia major: complete haematological remission under the combination of hydroxyurea and anagrelide. Br. J. Haematol (2002) 116:155–157.
  • YOON JM: Combination therapy for essential thrombocythemia. Blood (2002) American Society of Hematology (Abstract 4923).
  • RANDI ML, PUTTI MC: Essential thrombocythaemia in children: is a treatment needed? Expert Opin. Pharmacother. (2004) 5:1009–1014.
  • •A good overview on childhood essential thrombocythaemia.
  • CHINTAGUMPALA MM, STEUBER CP, MAHONEY DH et al.: Essential thrombo-cythemia in a child: management with anagrelide. Am J. Pediatr. Hematol amyl (1991) 13:52–56.
  • •First report on the use of anagrelide in children.
  • CHINTAGUMPALA MM, KENNEY LL, STEUBER CP: Treatment of essential thrombocythemia with anagrelide. Pediatr. (1995) 127:495–498.
  • HERMANN J, FUCHS D, SAUERBREY A et al.: Successful treatment of essential thrombocythemia with anagrelide in a child. Med. Ped. Oncol (1998) 30:367–371.
  • LACKNER H, URBAN C, BEHAM-SCHMID C et al.: Treatment of children with anagrelide for thrombocythemia. Ped Hematol/Oncol (1998) 20:469–473.
  • SCHERER S, FERRARI R, RISTER M: Treatment of essential thrombocythemia in childhood. Pediatr. Hematol Duca (2003) 20:361–365.
  • HONG Y, ERUSALIMSKY JD: Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review. Platelets (2003) 13:381–386.
  • •Compares the pharmacology of hydroxyurea and anagrelide.
  • FALANGA A, MARCHETTI M, EVANGELISTA V et al.: Polymorphnuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood (2000) 96:4261–4266.
  • ••A study showing granulocyte activation inpatients with essential thrombocythaemia.
  • CORTELAZZO S et al.: Hydroxyurea for patients with essential thrombocythemia and high risk of thrombosis. N Engl. I Med. (1995) 332:1132–1136.
  • ••An important trial on the role ofcytoreduction in thrombosis prevention.
  • FINAZZI G, RUGGERI M, REDEGHIERO F, BARBUI T: Second malignancies in patients with essential thrombocythemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized trial. Br. J. Haematol (2000) 116:923–924.
  • •The sequential use of busulphan and hydroxurea increases the risk of second malignancies.
  • RING T: Hydroxyurea in essential thrombocythemia. N Engl. J. Med. (1995) 333:803.
  • FEINER RH: Hydroxyurea in essential thrombocythemia. N Engl. J. Med. (1995) 333:803.
  • VAN GENDEREN PJ, MICHIELS JJ: Hydroxyurea in essential thrombocythemia. N Engl. J. Med. (1995) 333:802–803.
  • BRAVO BLANCO AM, MORAL JL, TEMBRAS S et al: Hydroxyurea induced skin ulcerations in patients with chronic myeloproliferative disorders. J. Hematother: Stem Cell Res. (2003) 12:461–463.
  • SCHWONZON M, SPANGENBERGER H, SPENGLER M: Hydroxyurea induced pneumonitis. Med. Kiln. (2003) 98:394–397.
  • BEST PJM, PETITT RM: Multiple skin cancers associated with hydroxyurea therapy. Mayo Clin. Proc. (1998) 73:961–963.
  • •Prolonged use of hydroxyurea may increase the rate of skin tumours.
  • BENNETT M, GRUNWALD AJ: Hydroxyurea and periodicity in myeloproliferative disease. Eur: Hematol (2001) 66:317–323.
  • BARBUI T, FINAZZI G, RUGGERI M, RODEGHIERO F: Secondary leukemia following hydroxyurea in patients with essential thrombocythemia: long term results of a randomized clinical trial. American Society of Hematology. Blood (1998) Suppl. 1:(Abstract 2016).
  • FURGERSON JL, VUKELJA SJ, BAKER WJ, O'ROURKE TJ: Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. Am. J. Hematol (1996) 51:137–140.
  • NAND S, STOCK W, GOD WIN J, FISHER SG: Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Am. Hematol (1996) 52:42–46.
  • •These authors cannot detect an increased risk of leukaemic transformation with hydroxyurea therapy.
  • NIELSEN I, HASSELBALCH HC: Acute leukemia and myelodysplasia in patients with a philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am. Hematol (2003) 74:26–31.
  • •These authors do not recommend the use of hydroxurea in younger patients.
  • FINAZZI G, RUGGERI M, RODEGHIERO F, BARBUI T: Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood (2003) 101:3749.
  • •The authors report no increased leukaemic transformation after long-term use of hydroxyurea.
  • VVEINFELD A, SWOLIN B, VVESTIN J: Acute leukemia after hydroxyurea therapy in polycythemia vera and allied disorders. Eur. Haematol (1994) 52:134–139.
  • STERKERS Y, PREUDHOMME C, LAI J-L et al.: Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood (1998) 91:616–622.
  • •High proportion of 17p deletion in patients with MDS/AML after treatment with hydroxyurea alone or in combination with pipobroman.
  • QUAGLINIO D, DILEONARDO, STATI M: Leukemic transformation in a case of thrombocythaemia. Case report and review of the literature. Acta Haematol (2001) 106:122–125.
  • SIRONI M, BERTOLA G, LODATO A et al.: Transition of essential thrombocythemia to megakaryoblastic leukaemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea. Acta Haematol (2003) 109:161-162. WAHLIN A, GOLOVLEVA I: Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Ph-negative essential thrombocythemia. Eur: Haematol (2003) 70:240–241.
  • RADIN Al, KIM HK, GRANT BW et al: Phase II study of a2 interferon in the treatment of the chronic myeloproliferative disorders (E5487) . Cancer (2003) 98:100–109.
  • ALVARADO Y, CORTES J, VERSTOVSEK S et al:. Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother. Pharmacol (2003) 51:81–86.
  • GOLUB R, ADAMS J, DAVE S, BENNETT CL: Cost effectiveness considerations in the treatment of essential thrombocythemia. Semin. Duca (2002) 29:(Suppl. 10):28–32.
  • BENNETT CL, VVEINBERG PO, GOLUB RIVI: Cost-effectiveness model of a Phase II clinical trial of a new pharmaceutical for essential thrombocythemia: is it helpful to policy makers? Semin. Hematol (1999) 36:(Suppl. 2):26–29.
  • GILBERT H: Clinical status of anagrelide: a selective agent for the control of thrombocythemia in myeloproliferative disorders. Cancer Invest. (1991) 9:343–344.
  • PETRIDES PE: Anagrelid: neues Therapeutikum bei Primärer Thrombozytose. Arzneimitteltherapie (1993) 11:71–73.
  • BEYKIRCH MK, TRAPP O, PETRIDES PE: Primäre Thrombozythämie. Diagnose und Therapie. Arzneimitteltherapie (1997) 15:309–311.
  • PETITT RM, PETRIDES PE: Platelet reductive treatment with anagrelide in thrombocythemic states: experiences in various centers and future directions. European working group on myeloproliferative disorders. Second Congress of the European Socie0, of Hematology Paris, France, May (1996).
  • SPENCER CM, BRODGEN, RN: Anagrelide. Drugs (1994) 47:809–822.
  • TEFFERI A, SILVERSTEIN MN, PETITT PM, MESA RA, SOLBERG LA: Anagrelide as a new platelet lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications. Sem. Thrombosis Hemostasis (1997) 23:379–383.
  • PETRIDES PE: Agrelin® (Anagrelide) is an efficacious platelet reducing drug in patients with primary thrombocythemia. Blood(1994) 84:5635a.
  • PETRIDES PE, TRAPP OM, BEYKIRCH MK: Anagrelide, a novel specific inhibitory agent for patients with primary thrombocythemia. Onkologie (1995) 17\(Suppl. 2):111.
  • PETRIDES PE: Treatment of essential thrombocythemia with Agrelin®: the German experience. Br. J. Haematol (1996) 93\(Suppl. 2):237 (Abstract 892).
  • PETRIDES PE, TRAPP OM, BEYKIRCH MK: Agrelin® (Anagrelide), a novel drug for the treatment for the treatment of primary thrombocytoses (ET, PV and CML): experience on 40 patients in Germany. Ann. Hematol (1996) 73(Suppl. II):A97.
  • PETRIDES PE, TRAPP OM, BEYKIRCH MK: Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count. Blood (1997) 90\(Suppl. 1) American Society of Hematology (Abstract 4009).
  • PETRIDES PE: Treatment of essential thrombocythemia with anagrelide in 60 patients from Germany. I Clin. Oncol (1997) 16:35a.
  • OERTEL MD: Anagrelide, a selective thrombocytopenic agent. Am. I Health System Pharm. (1998) 55:1979–1986.
  • BROOKS WG, STANLEY DD, GOODE J: Role of anagrelide in the treatment of thrombocytosis. Ann. Pharmacother: (1999) 33:1116–1121.
  • PESCATORE SL, SINDLEY C: Anagrelide: a novel agent for the treatment of myeloproliferative disorders. Expert Opin. Pharmacother. (2000) 1:537–546.
  • ANDERSSON BS: Essential thrombocythemia: diagnosis and treatment with special emphasis on the use of anagrelide. Hematology (2002) 7:173–177.
  • ADAMSON JW: Wither the platelet? N. Engl. J. Med. (1988) 318:1331–1332.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.